For the Treatment of Moderate to Severe Psoriasis, the Highest Proportion of Surveyed Dermatologists and MCOs Indicate Tha

However, Nearly Half of Surveyed Dermatologists Chose Remicade as the Most Efficacious Therapy for Moderate to Severe Psoriasis, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations’ (MCOs) pharmacy directors indicate that Abbott/Eisai’s Humira and Amgen/Pfizer/Stiefel/Takeda’s Enbrel have the best overall clinical profile when compared to other currently available agents. However, when asked to identify which available psoriasis agent was the most efficacious, most surveyed MCO pharmacy directors chose Humira or Enbrel while nearly half of surveyed dermatologists chose Centocor Ortho Biotech/Merck/Mitsubishi Tanabe’s Remicade.

The findings from Decision Resources’ analysis of the psoriasis drug market reveal that surveyed dermatologists who selected Remicade as the most efficacious agent reported higher satisfaction with the drug’s effect on psoriatic plaques at ten or 12 weeks than with any other efficacy attribute. In contrast, when asked to identify the most efficacious psoriasis therapy, surveyed MCO pharmacy directors identified Humira (45 percent) or Enbrel (41 percent), while only nine percent of surveyed MCO pharmacy directors selected Remicade. Additionally, despite robust efficacy data from clinical trials, only 13 percent of surveyed dermatologists selected Centocor Ortho Biotech/Janssen-Cilag’s Stelara—the first IL-12/23 inhibitor to launch for the indication—as the most efficacious therapy for moderate to severe psoriasis.

Although Enbrel, the current market leader in psoriasis, was selected as the most efficacious therapy by a slightly higher percentage of surveyed dermatologists than its closest competitor, Humira, the report findings suggest that Enbrel’s market position is at risk.

“Surveyed dermatologists who consider Enbrel the most efficacious drug gave it lower satisfaction scores on most efficacy attributes compared with the scores awarded to Humira by the surveyed dermatologists who selected it as the most efficacious,” said Decision Resources Therapeutic Area Director Madhuri Borde, Ph.D. “This perception of Enbrel’s inferior efficacy compared with other agents in its class is supported by clinical trial data.”

The findings also reveal that surveyed experts agree that long-term response with continuous therapy is one of the attributes that most influences their prescribing and tier placement decisions in moderate to severe psoriasis. Clinical data and the opinions of interviewed thought leaders indicate that Stelara has advantages on this attribute over Enbrel.

The continued uptake of interleukin inhibitors and TNF-alpha inhibitors and an almost twofold increase in the penetration of biologics in the moderate-to-severe population will drive a robust increase in the psoriasis drug market, from $3.4 billion in 2009 to more than $6.1 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Although Enbrel maintained its market dominance in 2009, it will face stiff competition from Humira and Stelara, which—along with the entry of biosimilar formulations—will lead to a decline of Enbrel’s market share from more than one-third of sales in 2009 to less than one-fifth of sales in 2019.

Decision Resources’ Robust Market Forecast and Opportunities Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2011 advisory service and the DecisionBase 2011 report series.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.

ICER said that Vertex's triplet CF therapy Trikafta would only be cost effective if the price were dropped from $311,000 to no more than $85,500.